文献速递前列腺癌

PSMA-PET时代高危前列腺癌「STAMPEDE样」队列:阿比特龙是否过度或过早?

Abiraterone for "STAMPEDE-Like" cohort of high-risk prostate cancer in the PSMA-PET era: too much, too early?
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-05-22

该研究评估PSMA-PET-CT分期的高危局部晚期前列腺癌「STAMPEDE样」队列,接受大分割放疗联合长期雄激素剥夺治疗(LT-ADT)而不加阿比特龙的长期生存。170例患者中位随访65个月,6年无转移生存率80.7%、前列腺癌特异性生存率95.8%、总生存率94.4%。结论提示对PSMA-PET-CT分期的高危患者,适当强化的局部治疗可能补充或替代全身强化。

要点

  • PSMA-PET-CT分期的高危前列腺癌,大分割放疗联合LT-ADT不加阿比特龙,6年MFS达80.7%。
  • 6年PCSS为95.8%、OS为94.4%,提示局部强化可能部分替代全身强化。
  • 多因素分析中Gleason评分和淋巴结分期与MFS显著相关。

核心结论

  • 对PSMA-PET-CT分期的高危前列腺癌,适当强化的局部治疗可能补充或替代全身强化。

研究设计与样本

  • 回顾性纳入2016至2021年符合「STAMPEDE高危」标准、PSMA-PET-CT分期为非转移性、接受外照射放疗的患者170例。
  • 放疗剂量为前列腺等效剂量>74 Gy,LT-ADT≥2年;采用Kaplan-Meier法分析MFS、PCSS和OS。

主要发现

  • 中位随访65个月,6年MFS、PCSS和OS分别为80.7%、95.8%和94.4%。
  • 约三分之一患者为淋巴结阳性并接受全盆腔放疗。
  • 多因素分析显示Gleason评分和淋巴结分期与MFS显著相关。

关键数值与推荐

  • 前列腺中位2Gy等效剂量为82 Gy。
  • LT-ADT持续时间≥2年。

临床怎么用

  • 对PSMA-PET-CT分期的高危非转移性前列腺癌,可考虑大分割放疗联合LT-ADT而不加阿比特龙,尤其适合选择性的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess long-term survival in a "STAMPEDE-like" cohort of high-risk locally advanced prostate cancer, staged with PSMA PET-CT, treated with hypofractionated radiotherapy (RT) and long-term androgen deprivation therapy (LT-ADT) without abiraterone. MATERIALS & METHODS: Patients with non-metastatic prostate cancer fulfilling "STAMPEDE high-risk" criteria, staged with PSMA PET-CT, treated with external beam RT from 2016 to 2021 were included. RT dose was >74 Gy equivalent to prostate with LT-ADT ≥ 2 years. We analysed metastatic-free survival (MFS), prostate cancer specific survival (PCSS) and overall survival (OS) using Kaplan-Meier method. RESULTS: 170 patients were eligible, treated with hypofractionated RT with median prostate 2Gy-equivalent dose of 82 Gy. About one-third were node-positive and treated with whole pelvic RT. Over median follow up of 65 months, 6-years MFS, PCSS and OS were 80.7%, 95.8% and 94.4% respectively. On multivariate analysis, Gleason score and nodal stage showed significant association with MFS. CONCLUSION: For PSMA-PETCT staged high risk prostate cancer, appropriately intensified local treatment could be complementary or an alternative to systemic intensification in selected patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Murthy V, Samanta A, Maitre P, et al. Abiraterone for "STAMPEDE-Like" cohort of high-risk prostate cancer in the PSMA-PET era: too much, too early? Prostate Cancer Prostatic Dis. 2025. PMID: 40404801. doi:10.1038/s41391-025-00983-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。